BALA CYNWYD, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
WideOpenWest, Inc. (NYSE - WOW)
Under the terms of the agreement, WOW will be acquired by affiliated investment funds of DigitalBridge Investments, LLC and Crestview Partners (“Crestview”) for $5.20 per share in cash for each share of common stock they own. The investigation concerns whether the WOW Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/wideopenwest-inc-nyse-wow/
BankFinancial Corporation (Nasdaq - BFIN)
Under the terms of the Merger Agreement, Bank Financial will be acquired by First Financial (Nasdaq - FFBC). Each outstanding share of BankFinancial common stock will be converted into the right to receive 0.48 of a share of First Financial common stock, valuing the transaction at approximately $142 million. The investigation concerns whether the BankFinancial Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/bankfinancial-corporation-nasdaq-bfin/.
STAAR Surgical Company (Nasdaq – STAA)
Under the terms of the Merger Agreement, STARR will be acquired by Alcon (NYSE - ALC) for $28.00 in cash for each share of STAAR they own. The transaction represents a total equity value of approximately $1.5 billion. The investigation concerns whether the STAAR Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/staar-surgical-company-nasdaq-staa/.
Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)
Under the terms of the agreement, Y-mAbs will be acquired by SERB Pharmaceuticals (“SERB”) for $8.60 in cash for each share of Y-mAbs they own. The transaction represents a total equity value of approximately $412 million. The investigation concerns whether the Y-mAbs Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/y-mabs-therapeutics-inc-nasdaq-ymab/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
